BioStock: Saniona’s Q4 Signals Value Ahead

Last week, biotech Saniona joined the life science reporting season when it published its report for the fourth quarter and year end 2021. The report underlines the advancements the company made during the past year, including the initiations of three clinical trials. BioStock contacted CEO Rami Levin for a comment.

Read the full interview with Rami Levin at biostock.se:

https://www.biostock.se/en/2022/03/sanionas-q4-signals-value-ahead/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/